All News
Ab1672 #ACR22 SSc on Women's Health
100 pts - 75% lSSc
59% sexuality aff by SSc (vag dryness 67%, dig ulcers 37%, GI 37%, dyspnea 20%)
48 pts dx during repro ys - 73% never discuss contraception, 30% didn't reach family plan
22 pt - 43 pregn, 33 birth: C-sxn, low bth wt
@Rheumnow https://t.co/JRkyCVEXLB
Eric Dein ericdeinmd ( View Tweet)
More than 25,000 #ACR22 tweets since November 1 - keep going strong today and we will reach 100,000,000 impressions. Congrats to @rheum_cat, @RheumNow and @CreakyJoints for having the most impact with over 10M impressions each. @ACRheum @StevenEchard https://t.co/K2Kr4sAicS
Steven Echard, CAE StevenEchard ( View Tweet)
Sometimes your RA pts are eligible for ICI cancer immunotherapy, but there’s hesitancy because of autoimmune risk/bad irAEs
@DanaFarber @MassGenBrigham:
more RA flares
but similar mortality, severe irAEs rates
Give them what they need!
ABST1667 @jeffsparks #ACR22 @RheumNow https://t.co/WdDP8IeIYG
David Liew drdavidliew ( View Tweet)
Sarilumab (SAR) + 14 wk GC taper demonstrated significant efficacy vs the comparator arm in steroid refractory PMR patients and improvement in quality of life. Sustained remission was 28.3% SAR vs 10.3% comparator arm. Spiera R Abs#1676 https://t.co/gXGJzbYLHK #ACR22 @RheumNow https://t.co/oZBsRtxMUw
Dr. Antoni Chan synovialjoints ( View Tweet)
Very interesting Thieves Market case... which I have also seen!
Don't forget mycoplasma pneumoniae-induced rash and mucositis (MIRM) when patients presen tw/oral ulceration
My patient had +ANA and carried a dx of PFAPA; only responded to abx!
#ACR22 @RheumNow ABSTR#TMO2 https://t.co/B9dBkZyrlN
Mike Putman EBRheum ( View Tweet)
What's your view look like? Are you in-person or virtual? Share a picture from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/DE7HhDzyJY
Dr. John Cush RheumNow ( View Tweet)
#abst1679 #acr22 @rheumnow CARRA STOP-JIA early introduction of bDMARD beneficial in polyarticular JIA: in early combination of cDMARD+biologic group > pts able to achieve Clinical Remission& significantly longer T spent in CID& cJADAS10 ID during the 3 year study vs step up Rx https://t.co/xwQJnSeCNE
Olga Petryna DrPetryna ( View Tweet)
Promising data on denosumab in erosive OA
Phase 2 study - less erosive progression, more symptom improvement
Abs# L05 @RheumNow #ACR22 https://t.co/9Fg3r02ZQG
Robert B Chao, MD doctorRBC ( View Tweet)
Wittoek et al. 48-week RCT of Denosumab in erosive hand OA. Prevents structural progression! @RheumNow #ACR22 Abstr#L05 #ACRbest https://t.co/CI6VBERSmn https://t.co/OszJkGeJF7
Richard Conway RichardPAConway ( View Tweet)
L05 #ACR22 High-dose Denosumab in Erosive Hand OA
48Wk, Double-blind PBO Phase 2 100 patients
GUSS change higher in DEN v PBO at w24, incr at w48
New erosions lower in DEN w48 (2% v 7%, OR 0.23, p<0.001)
Open label extension w improvement to baseline
@RheumNow https://t.co/X6MF9q2bKj
Eric Dein ericdeinmd ( View Tweet)
This single ctr retrospective cohort study by AOhayn on antiRo/La+ moms show that the mean timing of first fetal echo for CHB screening was at 20wks AOG.
💠CHB+ in 3 fetuses on 1st echo (done 19, 22.4, 29.3 wks)
Take home msg? Do timely CHB screens
#ACR22 @RheumNow ABST#0957 https://t.co/59crW0uov4
sheila RHEUMarampa ( View Tweet)
Walrabenstein et al. RCT of 16-week triple intervention - plant-based diet, exercise, stress management - vs usual care in OA. It works, but we don't know which component, or if Hawthorn effect @RheumNow #ACR22 Abstr#1644 https://t.co/p74Ptd8bZ2 https://t.co/EOg7RxRmO7
Richard Conway RichardPAConway ( View Tweet)
Maya Buch on major adverse CV events in tofa vs TNFi. Post-hoc analysis of phase 3b/4 data looking at cohort enriched for CV events.
@RheumNow #ACR22 #LateBreaking
Julian Segan JulianSegan ( View Tweet)
Fletcher et al. Epidemiology RA-ILD 2004-18 in VA. Incidence increased from 340 to 970/100,000PY. Prevalence increased 1.7% to 4.5%. More common males (4.81% vs 2.53%) and over 60 @RheumNow #ACR22 Abstr#1638 https://t.co/AbPgLUPoDz https://t.co/V25xDUwLbu
Richard Conway RichardPAConway ( View Tweet)
Askanase et al. Phase 2 RCT Cenerimod (S1P modulator) in SLE. Primary endpoint not met. Some suggestion of efficacy at highest 4mg dose. But if its already like this in a phase 2, I doubt a phase 3 will bring better results @RheumNow #ACR22 Abstr#1656 https://t.co/p4fcKW3cYD https://t.co/ha8xqeW6Xk
Richard Conway RichardPAConway ( View Tweet)
@RheumNow Assessing CV events in hierarchical order (each level has additional CV event). Hypothesis that increased CV events are driven by VTE in all-comers with the 10mg dose. https://t.co/IfRdJBERuA
Julian Segan JulianSegan ( View Tweet)
L06 #ACR22 ORAL Surveillance Updates!
Composite of all ischemic CV events and HF did NOT show difference b/w TOFA vs TNFi
But, MACE numerically higher with Tofa w/ h/o ASCVD
Highest CV risk in TOFA 10 mg BID, 2/2 VTE risk
Most important risk is pt's individual risks
@RheumNow https://t.co/jPPX7f5GRE
Eric Dein ericdeinmd ( View Tweet)
Dr S Hamroun shares their study data on factors assoc w/ time-to-conception in ♀️ w/ SpA:
❗Pre-conceptional NSAID use
❗Age
Thought-provoking.
Time to re-evaluate our NSAID prescribing practices for ♀️ SpA?
#ACR22 @RheumNow ABST#1673 https://t.co/cHED0I3vUe
sheila RHEUMarampa ( View Tweet)
This single ctr retro cohort study by Dr ZKazmi showed ⬇️HPV vax rates & ⬆️HPV infxn rates
🔅In HPV+ pts, risk of persistent HPV infxn was similar among ♀️ aged 21-26y & 27-45y (p>0.05)
Is it time for updated cervical ca screening guidelines for #lupus?
#ACR22 @RheumNow ABST#1671 https://t.co/7Nh62EYc6Y
sheila RHEUMarampa ( View Tweet)
Interesting study (MAGICA) of withdrawing TCZ in GCA after 1 year of therapy
Comparing abrupt vs gradual discontinuation
Very important clinical quesiton; kudos to FVSG for making this happen!
#ACR22 #Vasculitis22 @RheumNow https://t.co/912GCFik6L
Mike Putman EBRheum ( View Tweet)